Penno, Giuseppe
Solini, Anna
Bonora, Enzo
Orsi, Emanuela
Fondelli, Cecilia
Zerbini, Gianpaolo
Trevisan, Roberto
Vedovato, Monica
Cavalot, Franco
Laviola, Luigi
Nicolucci, Antonio
Pugliese, Giuseppe http://orcid.org/0000-0003-1574-0397
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Independent association of atherogenic dyslipidaemia with allācause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study
https://doi.org/10.1186/s12933-021-01224-7
Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-018-1133-z
Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study
https://doi.org/10.1136/bmjdrc-2020-001481
Risk of all-cause mortality according to the European Society of Cardiology risk categories in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-022-01942-8
Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1371/journal.pone.0125512
Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes
https://doi.org/10.1186/s12933-022-01706-2
Funding for this research was provided by:
Diabete Ricerca
Society for Endocrinology, Metabolism and Diabetes of South Africa
Eli Lilly and Company
Sigma-Tau
Boehringer Ingelheim
Chiesi Farmaceutici
Takeda Pharmaceutical Company
Article History
Received: 24 January 2018
Accepted: 17 March 2018
First Online: 24 March 2018
Compliance with ethical standards
:
: Dr. Penno reported receiving personal fees from Astra-Zeneca, Boehringer Ingelheim, Eli Lilly, and Merck Sharp & Dohme. Dr. Solini reported receiving grant from Astra-Zeneca and personal fees from Boehringer Ingelheim and Eli Lilly. Dr. Bonora reported receiving grants from Astra-Zeneca, Novo Nordisk, Roche, and Takeda and personal fees from Abbot, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi-Aventis, and Takeda. Dr. Orsi reported personal fees from Abbot, Astra-Zeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Novo Nordisk, Sanofi-Aventis, and Takeda. Dr. Trevisan reported receiving personal fees from Astra-Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Novartis, Novo Nordisk, and Sanofi-Aventis and grants from Astra-Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, and Sanofi-Aventis. Dr. Cavalot reported receiving personal fees from Astra-Zeneca, Sanofi-Aventis, and Takeda. Dr. Nicolucci reported receiving grants from Artsana, Astra-Zeneca, Eli Lilly, Novo Nordisk, and Sanofi-Aventis and personal fees from Eli Lilly and Novo Nordisk. Dr. Pugliese reported receiving personal fees from Astra-Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mylan, Shire, Sigma-Tau, and Takeda. No other disclosures were reported.
: The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. The study protocol was approved by the locally appointed ethics committees.
: Informed consent was obtained from all patients for being included in the study.